ChemiCare is a life-sciences spin-off from the Università degli Studi del Piemonte Orientale focused on discovering and developing therapies for severe neuromuscular and autoimmune disorders. Its lead program is CIC-39, a small-molecule candidate aimed at treating Duchenne Muscular Dystrophy as well as a range of autoimmune pathologies. The company’s stated objective is to advance CIC-39 into first-in-human clinical trials within the next 18 months. By translating academic research into clinically actionable therapies, ChemiCare seeks to deliver high-impact solutions for patients who currently have limited treatment options. The business model leverages close collaboration with academic labs while tapping external venture and public funds to finance development. The recent €2.5 million seed infusion provides the initial capital needed for pre-clinical work, regulatory preparation, and early manufacturing activities. No revenue, user, or previous funding metrics were disclosed in the article.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2025